National Bank of Canada’s Galectin Therapeutics GALT Stock Holding History

National Bank of Canada’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$779K	Buy	+167,900	New	+$435K	﹤0.01%	1331

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

RGF

Retirement Guys Formula Maumee, Ohio $266M AUM 25.32% 1-Year Est. Return

Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

National Bank of Canada's GALT Position: Q2 2026 in Review

National Bank of Canada opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 167,900 shares worth $779K. The stake represents ﹤0.01% of the portfolio and ranks #1331 among its holdings.

40 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

National Bank of Canada held 167,900 shares of Galectin Therapeutics worth $779K as of Q2 2026.
Galectin Therapeutics was a new National Bank of Canada position in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #1331 holding.
40 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.